타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706)) PENG YUAN·Gastric Cancer (GC) 143 trials | Pegylated liposomal doxorubicin (Pegylated liposomal doxorubicin) Merck Sharp & Dohme LLC·Ovarian Cancer 94 trials | |||
|---|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Cyclosporine | Iparomlimab and Tuvonralimab (QL1706) | Selinexor | Pegylated liposomal doxorubicin |
Overview Company | Roche / Genentech | Amsterdam Molecular Therapeutics | PENG YUAN | Qilu Pharmaceutical Co., Ltd. | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | VEGF-A | FRα | Gastric Cancer (GC) | FRα | Ovarian Cancer |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Chronic Myeloproliferative Disorders; Leukemia | Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer | NKTCL | Platinum-refractory Ovarian Carcinoma; Platinum-resistant Ovarian Cancer |
Overview Phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Overview Status | APPROVED | ACTIVE | RECRUITING | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | — | — | — | — |
Positioning Known limitation | downregulation across different drug combinations | — | — | — | — |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling | — | Targeting the nuclear export receptor | , Clinical and Translational Science |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat | biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics | biomarker after CRS+HIPEC and a therapeutic target | biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | Mouse | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706)) PENG YUAN·Gastric Cancer (GC) 143 trials | Pegylated liposomal doxorubicin (Pegylated liposomal doxorubicin) Merck Sharp & Dohme LLC·Ovarian Cancer 94 trials | |||
|---|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Cyclosporine | Iparomlimab and Tuvonralimab (QL1706) | Selinexor | Pegylated liposomal doxorubicin |
Overview Company | Roche / Genentech | Amsterdam Molecular Therapeutics | PENG YUAN | Qilu Pharmaceutical Co., Ltd. | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | VEGF-A | FRα | Gastric Cancer (GC) | FRα | Ovarian Cancer |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Chronic Myeloproliferative Disorders; Leukemia | Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer | NKTCL | Platinum-refractory Ovarian Carcinoma; Platinum-resistant Ovarian Cancer |
Overview Phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Overview Status | APPROVED | ACTIVE | RECRUITING | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | — | — | — | — |
Positioning Known limitation | downregulation across different drug combinations | — | — | — | — |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling | — | Targeting the nuclear export receptor | , Clinical and Translational Science |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat | biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics | biomarker after CRS+HIPEC and a therapeutic target | biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | Mouse | — | — | — |
추천 비교
추천 비교